Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

Shares of Compass Therapeutics (CMPX) fell more than 6% on Wednesday, heading for a third straight decline as analysts cut their price targets after a regulatory setback for the biotech’s lead cancer drug, Tovecimig.CMPX stock is also heading for its 10th decline in 12 sessions.Analyst Flags Higher…